These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 4778374)

  • 21. Interrelation between plasma magnesium and 25 hydroxy-vitamin D3 levels in chronic renal failure.
    Shany S; Kushelevsky A; Berlyne GM
    Biomedicine; 1977 Apr; 26(2):108-11. PubMed ID: 871518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypocalcemia, morbidity, and mortality in end-stage renal disease.
    Foley RN; Parfrey PS; Harnett JD; Kent GM; Hu L; O'Dea R; Murray DC; Barre PE
    Am J Nephrol; 1996; 16(5):386-93. PubMed ID: 8886175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlations between osteodensitometry and parameters of uremic osteodystrophy].
    Sforzini S; Viganò MR; Beretta P; Rosa M; d'Amico P; Lomuscio G; Paesani R
    Minerva Med; 1985 Mar; 76(9-10):445-8. PubMed ID: 3982703
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of 1,25-dihydroxycholecalciferol on calcium absorption, muscle weakness, and bone disease in chronic renal failure.
    Henderson RG; Russell RG; Ledingham JG; Smith R; Oliver DO; Walton RJ; Small DG; Preston C; Warner GT
    Lancet; 1974 Mar; 1(7854):379-84. PubMed ID: 4131033
    [No Abstract]   [Full Text] [Related]  

  • 25. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 26. 1-alpha-hydroxycholecalciferol for renal osteodystrophy.
    Brownjohn AM; Goodwin FJ; Hately W; Marsh FP; O'Riordan JL; Papapoulos SE
    Br Med J; 1977 Sep; 2(6089):721-3. PubMed ID: 912269
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biochemical changes in patients with chronic renal insufficiency during hemodialysis depending on whether or not they received 25-(OH)D3].
    Rico H; Naranjo P; Paniagua MC; Cordero M; Bordiu E; Charro A
    Rev Clin Esp; 1982 Oct; 167(1):45-7. PubMed ID: 7178586
    [No Abstract]   [Full Text] [Related]  

  • 28. [Long-term treatment of renalosteodystrophy with 1 alpha-hydroxycholecalciferol].
    Marco Franco JE; Alarcón Zurita A; Pizá Buñola C; Morey Molina A; Bestard Palmer J; Mairata Bosch S; Dalmau Diana M
    Rev Clin Esp; 1982 Jan; 164(1):33-5. PubMed ID: 7071401
    [No Abstract]   [Full Text] [Related]  

  • 29. [Variations in serum levels of phosphorus (iP), calcium (Ca), calcitonin (iCT) and parathormone (iPTH) in patients under periodic hemodialysis. Effects of exogenous calcitonin therapy].
    Bucciante G; Bernardi A; Biasia F; Milan G; Donato D
    Minerva Med; 1985 Mar; 76(9-10):415-7. PubMed ID: 3982698
    [No Abstract]   [Full Text] [Related]  

  • 30. Changes in serum phosphorus, calcium and alkaline phosphatase due to sucralfate.
    Vucelić B; Hadzić N; Gragas J; Puretić Z
    Int J Clin Pharmacol Ther Toxicol; 1986 Feb; 24(2):93-6. PubMed ID: 3514490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Phosphorus and calcium metabolism and its hormonal regulation in chronic kidney failure].
    Nikiforova NV; Strunin SE; Ermolenko VM; Mozzhechkov VT; Khomiakova VN
    Ter Arkh; 1985; 57(1):103-7. PubMed ID: 3983831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bone scintigraphy with 99mTc-labeled methylene diphosphonate in hemodialysis patients (author's transl)].
    Yamashita M; Aoki T; Kakiuchi T; Mabuchi H; Tabata Y; Murao Y; Nishizawa H; Maruyama Y; Kishi Y; Nakahashi H; Murakami K
    Radioisotopes; 1981 Nov; 30(11):609-11. PubMed ID: 6461029
    [No Abstract]   [Full Text] [Related]  

  • 33. [Parathyroidectomy in secondary hyperparathyroidism in chronic uremic patients under dialysis treatment. Development of the surgical strategy].
    Zucchi C
    Minerva Med; 1985 Mar; 76(9-10):397-401. PubMed ID: 3982697
    [No Abstract]   [Full Text] [Related]  

  • 34. [Diagnosis of anticonvulsant osteomalacia in adults (author's transl)].
    Krause KH; Prager P; Schmidt-Gayk H; Ritz E
    Dtsch Med Wochenschr; 1977 Dec; 102(51):1872-7. PubMed ID: 598289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study.
    Berl T; Berns AS; Hufer WE; Hammill K; Alfrey AC; Arnaud CD; Schrier RW
    Ann Intern Med; 1978 Jun; 88(6):774-80. PubMed ID: 208439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum 1,25-dihydroxycholecalciferol in anephric, haemodialyzed and kidney-transplanted patients. Effect of vitamin D3 supplement.
    Lund B; Clausen E; Friedberg M; Lund B; Moszkowicz M; Nielsen SP; Sørensen OH
    Nephron; 1980; 25(1):30-3. PubMed ID: 6243405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum 25-hydroxycholecalciferol in Greek uremics.
    Drivas G; Bamias J; Tsomis A; Kalos A; Douratsos D; Melissinos K
    Invest Urol; 1980 Jul; 18(1):52-3. PubMed ID: 7410014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Serum 25-OH-vitamin D in patients with hyperthyroidism].
    Gless KH; Hunstein W; Schmidt-Gayk H; Hüfner M
    Verh Dtsch Ges Inn Med; 1977 Apr 17-21; 83():1364-7. PubMed ID: 25526
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term effects of intravenous 1 alpha (OH)D3 combined with CaCO3 and low-calcium dialysis on secondary hyperparathyroidism and biochemical bone markers in patients on chronic hemodialysis.
    Brandi L; Daugaard H; Nielsen PK; Jensen LT; Egsmose C; Olgaard K
    Nephron; 1996; 74(1):89-103. PubMed ID: 8883025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Plasma concentrations of 25-hydroxycholecalciferol and anticonvulsant treatment].
    Baud L; Paunier L; Preece MA; O'Riordan JL; Sizonenko PC; Tchicaloff M
    Schweiz Med Wochenschr; 1974 Dec; 104(51):1908-10. PubMed ID: 4438987
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.